Onconetix Inc
ONCO
Get informed when a big investor buys or sells
+ FollowMarket Cap$400.84K
Close$
$1.24
13.4% upside
Current Fair Value
13.4% upsideUndervalued by 13.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $400,835.00 |
|---|---|
| Enterprise Value | $-3,025,315.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.73 |
| Beta | 3.01 |
| Outstanding Shares | 628,528 |
Return
| Return on Equity | -82.59% |
|---|---|
| Return on Assets | -65.41% |
| Return on Invested Capital | -65.47% |
Valuation & Multiples
| P/E Ratio | -0.08 |
|---|---|
| PEG | 0.15 |
| Price to Sales | 1.09 |
| Price to Book Ratio | 0.06 |
| Enterprise Value to Revenue | -4.11 |
| Enterprise Value to EBIT | 0.39 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.1 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 1, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 17, 2026
EPS Estimate
$-4505.00
Average shareholder expectationRevenue Estimate
$21,877
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.66%▲ 2.66% |
|---|---|
| Total Invested | $24,918 |
| Investors Holding | 5▲ 5.00% |
ESG Score
No data
About Onconetix Inc
3 employeesdeveloped by scientists at the prestigious oxford university in the uk, our vaccine protects against all influenza strains. it targets parts of the virus that are easy to induce a protective immune response against but also limited in...